Form 4: Ionis Pharmaceuticals CEO Brett P. Monia Sells Shares Under 10b5-1 Trading Plan

Ionis Pharmaceuticals CEO Brett P. Monia sold 140 shares of common stock at a price of $32.32 per share on March 11, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 11, 2025, Brett P. Monia, CEO of Ionis Pharmaceuticals, sold 140 shares of the company's common stock.
• The sale was executed at a price of $32.32 per share.
• Following the transaction, Monia directly owns 180,980 shares of Ionis Pharmaceuticals.
• The sale was conducted under a Rule 10b5-1 trading plan adopted on August 13, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily reflect a change in the CEO's outlook on the company.

Risks

• Sales by insiders, even under 10b5-1 plans, can sometimes be perceived negatively by the market.

Industry Context

Insider sales are a common occurrence in publicly traded companies, and sales executed under 10b5-1 plans are generally viewed as less impactful since they are pre-scheduled. Investors often monitor insider transactions for signals about a company's prospects, but these sales under pre-arranged plans are less likely to be indicative of management's current sentiment.

Stakeholder Impact

• The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is likely to be minimal given the pre-planned nature of the transaction.

Key Dates